Capricor resumes DMD trial, will seek funding

Capricor Therapeutics Inc. (NASDAQ:CAPR) resumed dosing in the Phase II HOPE-2 trial of IV CAP-1002 for Duchenne muscular dystrophy

Read the full 193 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE